SMC approves Bavencio for bladder cancer
Merck and Pfizer’s Bavencio (avelumab) has been approved by the Scottish Medicines Consortium (SMC) for use via NHS Scotland as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma ...
August 11, 2021
by pharmatimes
Preliminary NICE 'no' for Merck's Bavencio
The National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.
May 7, 2021
by pharmatimes
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Merck and Pfizer Inc. today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are ...
January 25, 2021
by prnasia
Bavencio, Imbruvica among latest SMC decisions
In its latest guidance, the Scottish Medicines Consortium (SMC) has accepted eight new medicines for use by NHS Scotland.
October 15, 2020
by pharmatimes
UK bladder cancer patients get early access to Bavencio
Merck and Pfizer’s Bavencio (avelumab) is now available under the UK's Early Access to Medicines Scheme (EAMS) giving some patients with bladder cancer the chance to receive treatment with the immunotherapy before its approval in Europe.
September 4, 2020
by pharmatimes
NICE green light for immunotherapy Bavencio
The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
September 3, 2020
by pharmatimes
NICE backs Bavencio combo for kidney cancer
The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
July 31, 2020
by pharmatimes
US approves Bavencio for bladder cancer
EMD Serono, the biopharmaceutical business of Merck KGaA, and Pfizer announced that the US Food and Drug Administration (FDA) has expanded use of Bavencio (avelumab) to include maintenance treatment of patients ...
July 2, 2020
by pharmatimes
EMA to consider expanding use of Merck/Pfizer's Bavencio
The European Medicines Agency has validated for review Merck and Pfizer's application to market Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).
June 23, 2020
by pharmatimes
EMD Serono, Pfizer Receive Breakthrough Therapy Designation, Submit Application for BAVENCIO
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer announced completion of the submission.
April 15, 2020
by americanpharmaceuticalreview
Merck, Pfizer terminate Bavencio head and neck cancer trial
Merck KGaA and Pfizer have decided to stop their Phase III JAVELIN study testing Bavencio (avelumab) as a potential treatment for certain patients with advanced head and neck cancer.
March 17, 2020
by pharmatimes
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The results of the study will be submitted for presentation at an upcoming medical congress and shared with the US Food and Drug Administration (FDA) and other health authorities.
January 6, 2020
by prnasia